Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jingxin, Hou, Lihua, Guo, Xiling, Jin, Pengfei, Wu, Shipo, Zhu, Jiahong, Pan, Hongxing, Wang, Xue, Song, Zhizhou, Wan, Jingxuan, Cui, Lunbiao, Li, Junqiang, Chen, Yin, Wang, Xuewen, Jin, Lairun, Liu, Jingxian, Shi, Fengjuan, Xu, Xiaoyu, Zhu, Tao, Chen, Wei, Zhu, Fengcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863573/
https://www.ncbi.nlm.nih.gov/pubmed/35087233
http://dx.doi.org/10.1038/s41591-021-01677-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863573/
https://www.ncbi.nlm.nih.gov/pubmed/35087233
http://dx.doi.org/10.1038/s41591-021-01677-z

Ejemplares similares